NSAIDs in CAD Patients
|
|
- Dennis Todd
- 7 years ago
- Views:
Transcription
1 NSAIDs in CAD Patients Mikhail Torosoff, MD, PhD, FACC Assistant Professor of Medicine Division of Cardiology Department of Medicine Albany Medical College
2
3 Cardiovascular Side Effects of NSAIDs Pathophysiology of Cyclooxygenase Inhibition
4 Pathophysiology: Effects of Cox-1 and Cox-2 Inhibition Cyclooxygenase-1 Arachidonic acid Prostaglandins Cyclooxygenase-2 Prostanoids TxA 2 PGE 2 PGI 2 Gastric Mucosa Platelets Kidney Vessels Endothelium Gastric ulceration Bleeding Na + retention BP edema Vasospasm Thrombosis Needeleman Proc Nat Acad Sci 1979; 76: 944; Marcus J Lipid Res 1984; 25: 151; Buerke Circulation 2004; 110: 2053; FitzGerald GA, Patrono C. Clin Exp Rheumatol. 2001;19(suppl 25):S31-S36; Robert A. Annu Rev Pharmacol Toxicol. 1998;38:97-120; Pairet M, Engelhardt G. Fundam Clin Pharmacol. 1996;10:1-15; Weksler BB et al. Proc Natl Acad Sci U S A. 1977;74: ; Whelton A. Am J Med. 2001;110(suppl 3A):33S-42S; Vane JR et al Annu Rev Pharmacol Toxicol. 1998;38:97-120; Fosslien E Ann Clin Lab 1998;28:67-81; Vane JR Nat New Biol. 1971;231: ; Gierse JK et al Biochem J. 1995;305: ; Robert A Gastroenterology. 1979;77: ; Pairet M, Engelhardt G Fundam Clin Pharmacol. 1996;10:1-15.
5 Cox-2 IC 50 ( mol/l) Pathophysiology: All NSAIDs inhibit Cox-1 and Cox Fewer CV & Renal Complications 10 Ibuprofen Naproxen Acetaminophen More CV & Renal Complications Indomethacin Diclofenac Meloxicam Celecoxib Nimesulide More GI Complications Cox-1 IC 50 ( mol/l) Valdecoxib Rofecoxib Fewer GI Complications Patrignani P et al J Physiol Pharmacol 1997; 48:623-31; Chan C-C et al J Pharmacol Exp Ther 1999;290:551-60; Warner TD et al Proc Natl Acad Sci U S A 1999;96: [Erratum, Proc Natl Acad Sci U S A 1999;96:9666.]; Cryer B et al Am J Med 1998;104:413-21; Gierse et al The Journal of Pharmacology And Experimental Therapeutics October 19, 2004;
6 Cardiovascular Side Effects of NSAIDs Hypertension Congestive Heart Failure Stroke Myocardial Infarction
7
8 Medi-Cal: NSAIDs and Risk for AMI Medi-Cal Population (>18 Years) With Physician-Diagnosed Arthritis ( )* OR for AMI (95% CI) Remote use Indomethacin Sulindac Meloxicam Rofecoxib Ibuprofen Celecoxib Naproxen Valdecoxib Nabumetone 1.00 (reference) 1.71 ( ); P< ( ); P< ( ); P< ( ); P< ( ); P< ( ); P< ( ); P= ( ); P= ( ); P= *2,356,885 person-years of follow-up; 15,343 cases of AMI. Singh et al. Ann Rheum Dis. 2005;64(suppl III):85.
9
10
11
12
13 Risk of CV Events with NSAIDs: The Nurses Health Study 121,701 female RNs; 12 years FU = 765,626 patient-years FU 2041 CV events: 814 MIs, 795 CVAs fatal MIs fatal CVAs 327 cases / patient-years after 1998 Days Per Week: None Tabs Per Week: None >14 More Events Chan et al. Circulation 2006 DOI Age-Adjusted Relative Risk (95% CI)
14 Risk of CV Events with Acetaminophen: The Nurses Health Study 121,701 female RNs; 12 years FU = 765,626 patient-years FU 2041 CV events: 814 MIs, 795 CVAs fatal MIs fatal CVAs 326 cases / patient-years after 1998 Days Per Week: None Tabs Per Week: None >14 More Events Chan et al. Circulation 2006 DOI Age-Adjusted Relative Risk (95% CI)
15
16 Distinguishing between Selective vs. Non-Selective Cox-2 Inhibitors ASA, Coxibs, NS-NSAIDs, and Myocardial Infarction
17 Acute Coronary Syndromes Unobstructed lumen Diseased Endothelium Platelet Rich Thrombus Ruptured plaque
18 Death or MI (%) Death or MI (%) ASA is Cardio-protective in Primary and Secondary Prevention Placebo ASA In 2ry Prevention 5 4 Placebo ASA In 1ry Prevention Lewis Cairns Theroux RISC 0 Anti-Platelet Trialists Braunwald et al. Heart Disease, 6 th Edition. pp.1244, 2117, 2119
19 Oral Antiplatelet Agents Mechanism of Action clopidogrel ticlopidine HCl ADP dipyridamole phosphodiesterase Integrillin Aggrastat Gp IIb/IIIa (Fibrinogen Receptor) COX-1 ADP Activation Collagen Thrombin TXA 2 aspirin TXA 2 ADP = adenosine diphosphate, TXA 2 = thromboxane A 2, COX = cyclooxygenase. Schafer AI. Am J Med. 1996;101:
20 Proportion Surviving (%) NSAIDs negate ASA Cardioprotection survivors of AMI ASA ASA+NSAID ASA+Ibuprofen ASA vs ASA+Ibuprofen 1.9x risk of MI ( ) P= Follow-Up (years) MacDonald T et Wei L Effect of ibuprofen on cardio-protective effect of aspirin Lancet 2003:361:
21 April 2005 FDA statement on NSAIDs Boxed warning for increased risk of CV events and GI bleeding associated with all prescription NSAIDs For all prescription NSAIDs, FDA requested a contraindication for use in patients who have recently undergone CABG surgery The labeling for OTC NSAIDs has been revised to include more specific information about potential CV and GI risks and information to remind patients of the limited dose and duration of treatment of these products in accordance with the package instructions Lack of consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events OTC=over the counter. April 6, Public Health Advisory. Available at: Accessed September 15, 2005.
22 Cumulative MI Incidence (%) Risk of CV Events with NSAIDs: Physicians Health Study 22,071 healthy MDs randomized to ASA vs. placebo, 5 year f/u 378 MIs: 139 in ASA group vs. 239 in placebo group, p< ASA group 2 Placebo Aspirin NSAIDs 1-60d/y NSAIDs >60d/y Placebo group NSAIDs 1-60d/y NSAIDs >60d/y More MIs Time (months) Relative Risk of MI (times) Kurth T et al. Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs. Circulation 2003, 108:
23
24 Platelet Inhibition, ASA, NSAIDs, and Selective Cox-2 Inhibitors Platelet Aggregation Inhibition (%) ASA before Ibuprofen Rofecoxib before ASA Ibuprofen Before ASA Hours Catella Lawson - Vioxx Ibuprofen ASA vs Tx and Platelet Aggregation - NEJM
25 Patients were post-discharge after first CVD admission all on low-dose ASA N=7107 Ibuprofen Clinically Diminishes the Cardioprotective Effect of ASA All-cause Mortality 95% CI* ASA alone 1.00 NS ASA + ibuprofen 1.93 P= CV Mortality 95% CI* ASA + ibuprofen 1.73 P= *Adjusted for age; sex; Carstairs social deprivation score; previous admission for CVD, diabetes mellitus, RA, or OA; drug use for CVD or diabetes; disease-modifying antirheumatic drug use; lipid-lowering drug use at discharge; and interaction between length of ASA exposure and duration of ibuprofen, diclofenac, or other NSAID use MacDonald TM, et al. Lancet. 2003;361:
26 Sept 2006 FDA statement on NSAIDs
27 Ibuprofen and Aspirin Interaction: Attenuation of the Anti-Platelet Effect of Aspirin Healthcare professionals should be aware of an interaction between low dose aspirin (81 mg per day) and ibuprofen which might render aspirin less effective when used for its anti-platelet cardioprotective effect. Healthcare professionals should advise consumers and patients regarding the appropriate concomitant use of ibuprofen and aspirin. Other nonselective OTC NSAIDs should be viewed as having potential to interfere with the antiplatelet effect of low-dose aspirin unless proven otherwise. Analgesics that do not interfere with the antiplatelet effect of low dose aspirin should be considered for populations at high risk for cardiovascular events. FDA Scientific Statement 9/2006
28 Interaction of Naproxen with Aspirin Naproxen interfered with the inhibitory effect of aspirin on platelet COX-1 activity and function. This pharmacodynamic interaction might undermine the sustained inhibition of platelet COX-1 that is necessary for aspirin s cardioprotective effects. M. Capone et al. J Am Coll Cardiol 2005;45:1295.
29 Closure Time (sec) NSAID-ASA Interaction Placebo Naproxen Celecoxib Ibuprofen Indomethacin AM ASA 50 8 AM Dose 1 8 PM Dose 2 8 AM Dose 3 0 Day 1 Day 2 Day 3 Gladding NSAIDs and ASA Interaction AJC
30
31
32
33 NY Medicare P&T Committee Formulary Update Patients treated with ASA for CV Indications may be prescribed Celecoxib without prior authorization
34 AMCH Formulary Recommendations: With the exception of aspirin, all NSAID s are considered to be contraindicated in patients: Undergoing CABG in the immediate post operative period Undergoing PCI Acute Coronary Syndrome / AMI Orders for NSAID s, with the exception of aspirin, will be auto-discontinued in these patients. For patients receiving chronic maintenance aspirin therapy for CV indications ischemic stroke or TIA, atrial fibrillation, CAD, prosthetic heart valves, chronic extremity arterial insufficiency, following vascular surgery or PCI NSAID s are considered to be contraindicated. In these patients, acetaminophen or the selective COX-2 inhibitor, celecoxib (Celebrex ) not to exceed 200mg/day may be used. Orders for NSAID s, with the exception of celecoxib, will be auto-discontinued in these patients. For patients requiring an NSAID for analgesia, acetaminophen or celecoxib (Celebrex ) not to exceed 200mg/day may be used.
35 Addendum
36 Effectiveness of Individual Therapies From Evidence-Based Trials Deaths caused Deaths prevented ACE Inhibitors in CHF Beta Blockers in CHF Aldosterone Blockers in CHF ASA in High Risk CAD Patients ASA in Low Risk CAD Patients NSAIDs in CAD Patients on ASA Events per 1000 patient-years of Rx Remme WJ et al. Eur. Heart J. 2001;22: , N Engl J Med 2003;348: Antiplatelet Trialists Collaborative Group BMJ
37 Rofecoxib, Celecoxib, and Valdecoxib: Not all medications are born equal Randomized Trials with Adverse Outcomes ROFECOXIB VALDECOXIB CELECOXIB Total number of patients enrolled 25,273 pts 14,372 pts 44,307 pts Trials with adverse trend 7 of 18 2 of 21 1 of 41 Patients with adverse events Any CABG Polyposis Dose of the drug Low: qd IV dosing High: 400 bid FDA Panel Vote 2/18/ (2) 31-1 Pharmacokinetics, pharmacodynamics, and metabolism Oral bioavailability (%) Elimination half-life (hr) Appr. 11 Volume of distribution (liters) ±166 Main pathway of metabolism Reduction Glucuronidation Oxidation Active Metabolites Present None None Metabolite-to-parent conversion Up to 20% None None Juni Vioxx Metaanalysis - Lancet White Celebrex Metaanalysis AJC Nicoll - Bioorg Med Chem Letters ; Halpin - Drug Met Disp ; Halpin - Drug Met Disp
38 Meta-analysis Cardiovascular Death, MI, and Stroke: Celecoxib vs ns-nsaids Celecoxib 200 mg daily (N=19,773) ns-nsaids (N=13,990) Patient-years Mean exposure/patient (mo) CV death, MI, stroke (n [%]) 57 (1.0) 54 (1.2) CV death 15 (0.3) 19 (0.4) MI 35 (0.6) 19 (0.4) Stroke 7 (0.1) 16 (0.4) Most common side effects were dyspepsia, diarrhea, and abdominal pain, and were generally mild to moderate. CELEBREX should be used in pregnancy only if the potential benefit outweighs the potential risk to the fetus. CELEBREX should be avoided during late pregnancy. Treatment with CELEBREX is not recommended in those patients with advanced renal disease. n=events per 100 patient-years. FDA Advisory Committee Meeting. February 16, 2005.
39 Adjusted Relative Risk of AMI Among Medicare Beneficiaries Selective COX-2 Inhibitor Reference Group Adjusted Odds Ratio (95% CI) Celecoxib No NSAID or coxib 0.93 ( ) Celecoxib Naproxen 0.95 ( ) Celecoxib Ibuprofen 0.98 ( ) Celecoxib Other NSAIDs 0.95 ( ) Rofecoxib Celecoxib 1.24 ( ) Rofecoxib No NSAID or coxib 1.14 ( ) Rofecoxib Naproxen 1.17 ( ) Rofecoxib Ibuprofen 1.21 ( ) Rofecoxib Other NSAIDs 1.17 ( ) Solomon et al. Circulation. 2004;109:
Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationL'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationVIOXX Gastrointestinal Outcomes Research Trial (VIGOR) Bonnie Goldmann, M.D. Regulatory Affairs Merck Research Laboratories
VIOXX Gastrointestinal Outcomes Research Trial (VIGOR) Bonnie Goldmann, M.D. Regulatory Affairs Merck Research Laboratories 1 Arachidonic Acid CO 2 H COX-1 NSAIDs COX-2 Prostanoids Prostanoids Protection
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationUse of Aspirin and NSAIDS in patients with Heart Disease
Use of Aspirin and NSAIDS in patients with Heart Disease Shawn W. Robinson, MD Assistant Professor of Medicine, Physiology University of Maryland School of Medicine Chief of Cardiology, VA Maryland Health
More informationArticles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Journal Presentation
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationA. Ketorolac*** B. Naproxen C. Ibuprofen D. Celecoxib
1. A man, 66 years of age, with a history of knee osteoarthritis (OA) is experiencing increasing pain at rest and with physical activity. He also has a history of depression and coronary artery disease.
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationAntiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationNew Approaches to, and Indications for, Antiplatelet Therapy
New Approaches to, and Indications for, Antiplatelet Therapy Kenneth A. Bauer, MD Professor of Medicine, Harvard Medical School Chief, Hematology Section, VA Boston Healthcare System Director, Thrombosis
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationBreaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice
Breaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice Antiplatelets and oral anticoagulants Aspirin Plavix Prasugrel Ticagrelor Apixaban Rivaroxaban Dabigatran- Direct thrombin inhibitor
More informationIssues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW
1 Issues and Challenges in ACS Management Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW 2 Disclaimer Presentation are intended for educational purposes only and do not replace independent professional
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationThrombosis and Bleeding
Many questions, few answers Thrombosis and Bleeding Pierre Noel MD Mayo Arizona Scope of the Problem Thrombosis PV 12-39% ET 11-25% MF 10% 60-70% of thrombosis are arterial Splanchnic and cerebral thrombosis
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationA. Approval for the indications of osteoarthritis and rheumatoid arthritis at a dose of 10mg/day and dysmenorrhea at a dose of 20-mg bid as needed.
Agent: Valdecoxib Indication: Analgesia, Dysmenorrhea Osteoarthritis, and Rheumatoid Arthritis Reviewer: Kent Johnson, MD Date: November 7, 2001 NDA: 21,341 EXECUTIVE SUMMARY 1-RECOMMENDATIONS A. Approval
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationPerioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time
Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationMedications in Stroke Rehabilitation THE GOALS OF PRESENTATION STROKE STATISTICS 9/9/2014
Medications in Stroke Rehabilitation THE GOALS OF PRESENTATION IDENTIFY POTENTIAL AREAS FOR PHARMACOLOGIC INTERVENTIONS IN THE STROKE REHAB PATIENT IDENTIFY AGENTS USED WITH GENERAL MECHANISM OF ACTION
More informationNIMULID MD. 1. Introduction. 2. Nimulid MD Drug delivery system
NIMULID MD 1. Introduction Nimulid MD is a flavoured dispersible Nimesulide tablet with fast mouth dissolving characteristics thereby providing immediate relief. Nimesulide is a non-steroidal antiinflammatory
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationUniversity of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationFOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationAntiplatelet therapy:
Balanced information for better care Antiplatelet therapy: Aggregating the latest evidence Evaluating the choices for a preventive therapy with impressive benefits and important risks Antiplatelet agents
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationWhat s the Deal with NSAIDs?
Focus on CME at the Memorial xxx University of Newfoundland What s the Deal with NSAIDs? Majed M. Khraishi, MB, BCh, FRCPC Presented at Wednesday at Noon Ask the Consultant Arthritis is one of the most
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationManagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationAnalgesics for Osteoarthritis: An Update of the
Comparative Effectiveness Review Number 38 Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Comparative Effectiveness Review Number 38 Analgesics for Osteoarthritis:
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationHYPERCHOLESTEROLAEMIA STATIN AND BEYOND
HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause
More informationOptimal Duration of Dual Antiplatelet Therapy
Optimal Duration of Dual Antiplatelet Therapy Luis A Guzman, MD, FACC, FSCAI Associate Professor of Medicine Director, Cardiac and Vascular Cath Lab University of Florida College of Medicine - Jacksonville
More informationAddendum to Clinical Review for NDA 22-512
Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationGuidelines for Use of Clopidogrel (Plavix )
East Lancashire Medicines Management Board representing East Lancashire Hospitals NHS Trust, Lancashire Care Trust, Blackburn with Darwen PCT, East Lancs PCT Licensed Indications Guidelines for Use of
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationPlatelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.
Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University
More informationChoosing Pain Medicine for Osteoarthritis. A Guide for Consumers
Choosing Pain Medicine for Osteoarthritis A Guide for Consumers Fast Facts on Pain Relievers Acetaminophen (Tylenol ) works on mild pain and has fewer risks than other pain pills. Prescription (Rx) pain
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationComparative Effectiveness Review Number 4. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis
This report is based on research conducted by the Oregon Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0024).
More informationMaking Sense of the New Statin guidelines. They are more than just lowering your cholesterol!
Making Sense of the New Statin guidelines They are more than just lowering your cholesterol! No Disclosures Margaret (Peg) O Donnell DNPs, FNP, ANP B-C, FAANP Senior Nurse Practitioner South Nassau Communities
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationIl punto sulla terapia antitrombotica nelle sindromi coronariche acute
Santa Margherita Ligure TIGULLIO CARDIOLOGIA 2012 16-17 Febbrajo 2012 Il trattamento dell infarto miocardico acuto ad ST spraslivellato: dal territorio al laboratorio di emodinamica Il punto sulla terapia
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationCHAPTER 1 INTRODUCTION
CHAPTER 1 INTRODUCTION Rheumatoid Arthritis (RA) is a chronic syndrome characterised by non-specific, usually symmetric inflammation of the peripheral joints, potentially resulting in progressive destruction
More informationTo Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC
To Bridge or Not to Bridge Periop Anticoagulation Management Don Weinshenker, MD Ambulatory Care Denver VAMC Financial Disclosure Information Nothing to report Periop AC Management Chronically anti-coagulated
More informationMarco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo
Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on
More informationAtherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationStroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More information